Ghamami Niousha, Chiang Sandy Hsiang Yu, Dormuth Colin, Wright James M
Biology and Pharmacology, McMaster University, 1280 Main Street West, Hamilton, ON, Canada, L8S 4L8.
Cochrane Database Syst Rev. 2014 Aug 31;2014(8):CD010052. doi: 10.1002/14651858.CD010052.pub2.
Calcium channel blockers are a heterogeneous class of drugs, including dihydropyridine and non-dihydropyridine subgroups, commonly used in the treatment of hypertension. A systematic review of the 24-hour time course of the blood pressure-lowering effect has not been published.
To assess how much variation there is in hourly systolic and diastolic blood pressure lowering by dihydropyridine calcium channel blockers over a 24-hour period in people with hypertension aged 18 years or over, with baseline systolic blood pressure of at least 140 mmHg or diastolic blood pressure of at least 90 mmHg, or both.
We performed electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2014), MEDLINE (1946 to February 2014), EMBASE (1974 to February 2014), and ClinicalTrials.gov (to February 2014). We also screened references of published studies and reviews to identify additional trials.
We included all randomized, placebo-controlled trials assessing the hourly effects of dihydropyridine calcium channel blockers by ambulatory blood pressure monitoring in adults with hypertension with a follow-up of at least three weeks.
Two authors independently selected the included trials, evaluated the risk of bias, and analyzed the data.
We included 16 randomized controlled trials of dihydropyridine calcium channel blockers in this systematic review, with 2768 randomized participants. Drugs studied included amlodipine, lercanidipine, mandipine, nifedipine, and felodipine (all administered once daily) and nicardipine (administered twice daily). We analyzed and presented data by hour post dose. The blood pressure-lowering effect was stable over time; there were no clinically important differences in blood pressure-lowering effect of calcium channel blockers between each hour for either systolic blood pressure (estimated mean hourly differences ranged between 9.45 mmHg and 13.2 mmHg) or diastolic blood pressure (estimated mean hourly differences ranged between 5.85 mmHg and 8.5 mmHg). However, there was a moderate risk of bias for this finding. Once-daily dihydropyridine calcium channel blockers appeared to lower blood pressure by a relatively constant amount throughout the 24-hour dosing interval.
AUTHORS' CONCLUSIONS: Six dihydropyridine calcium channel blockers studied in this review lowered blood pressure by a relatively similar amount each hour over the course of 24 hours. The benefits and harms of this pattern of blood pressure lowering are unknown. Further trials are needed with accurate recording of time of drug intake and with reporting of standard deviation of blood pressure at each hour. We did not attempt to assess adverse effects in this review due to the lack of reporting and the short duration of follow-up.
钙通道阻滞剂是一类异质性药物,包括二氢吡啶类和非二氢吡啶类亚组,常用于治疗高血压。关于其降压作用24小时时间进程的系统评价尚未发表。
评估年龄在18岁及以上、基线收缩压至少为140 mmHg或舒张压至少为90 mmHg或两者兼具的高血压患者,二氢吡啶类钙通道阻滞剂在24小时内每小时降低收缩压和舒张压的差异有多大。
我们对Cochrane对照试验中心注册库(CENTRAL)(2014年第1期)、MEDLINE(1946年至2014年2月)、EMBASE(1974年至2014年2月)和ClinicalTrials.gov(至2014年2月)进行了电子检索。我们还筛选了已发表研究和综述的参考文献以识别其他试验。
我们纳入了所有通过动态血压监测评估二氢吡啶类钙通道阻滞剂每小时效果的随机、安慰剂对照试验,这些试验的受试者为高血压成人,随访时间至少为三周。
两位作者独立选择纳入的试验、评估偏倚风险并分析数据。
在本系统评价中,我们纳入了16项二氢吡啶类钙通道阻滞剂的随机对照试验,共有2768名随机分组的参与者。研究的药物包括氨氯地平、乐卡地平、马尼地平、硝苯地平、非洛地平(均每日给药一次)和尼卡地平(每日给药两次)。我们按给药后小时数分析并呈现数据。降压效果随时间稳定;钙通道阻滞剂在每小时降低收缩压(估计平均每小时差异在9.45 mmHg至13.2 mmHg之间)或舒张压(估计平均每小时差异在5.85 mmHg至8.5 mmHg之间)方面,降压效果无临床重要差异。然而,这一发现存在中度偏倚风险。每日一次的二氢吡啶类钙通道阻滞剂在整个24小时给药间隔内似乎能以相对恒定幅度降低血压。
本综述中研究的六种二氢吡啶类钙通道阻滞剂在24小时内每小时降低血压的幅度相对相似。这种降压模式的益处和危害尚不清楚。需要进一步开展试验,准确记录药物摄入时间并报告每小时血压的标准差。由于缺乏报告以及随访时间短,我们在本综述中未尝试评估不良反应。